•
Sep 30, 2022
Mink Therapeutics Q3 2022 Earnings Report
Reported financial results for the third quarter of 2022 and provided a corporate update.
Key Takeaways
MiNK Therapeutics reported a net loss of $6.3 million for the third quarter of 2022, with a cash balance of $24.2 million at the end of the quarter. The company highlighted progress in clinical programs, next-generation pipeline development, and scaling up internal cGMP manufacturing capabilities.
Ended the third quarter 2022 with a cash balance of $24.2 million.
Cash used in operations for the third quarter ended September 30, 2022, was $5.6 million.
Net loss for the quarter ended September 30, 2022, was $6.3 million or $0.19 per share.
Five abstracts accepted for presentation at Society of Cancer Immunotherapy 37th Annual Meeting, November 8th to 12th.